secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apyx Medical Corp (APYX)
CIK:        0000719135
Form:       8-K
Filed at:   2023-03-16T23:59:59+00:00
Accession:  0000719135-23-000015
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apyx Medical Q4 2022 revenue down 25% to $12.6M; net loss $6.0M; guides 2023 rev $58-61M
--------------------------------------------------------------------------------

- Q4 total revenue $12.6M (-25% YoY); Advanced Energy segment $10.5M (-30% YoY); OEM $2.1M (+15% YoY).
- FY2022 net loss $23.2M ($0.67/share) vs $15.2M in 2021; adjusted EBITDA loss $15.4M vs $8.8M.
- Introduces FY2023 guidance: total revenue $58-61M (30-37% growth); net loss ~$14M vs $23.2M in 2022.
- Post-quarter: FDA 510(k) clearance for Renuvion APR Handpiece (Feb 27); $35M credit facility with MidCap Financial.
- CEO cites FDA Safety Communication disruption; expects >35% Advanced Energy growth in 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/719135/000071913523000015/0000719135-23-000015-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/719135/000071913523000015/apyx-20230316.htm
  HTML page:      https://secwatch.observer/filing/0000719135-23-000015

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer